-
California College Launches Nation's First Psychedelic Studies Degree For Undergraduates
Thursday, November 7, 2024 - 3:12pm | 704Read More...Starting in 2025, students at the California Institute of Integral Studies (CIIS) in San Francisco will be able to pursue a unique academic path: a bachelor's degree in psychedelics studies. This marks the first time an accredited institution in the United States has offered an undergraduate degree...
-
Analysts Defend Esperion As Shares Sell Off Sharply
Thursday, May 3, 2018 - 11:17am | 460Read More...Esperion Therapeutics Inc (NASDAQ: ESPR) stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. While the company hit its primary endpoints with the trial, patients in the test group experienced a higher...
-
As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside
Monday, November 27, 2017 - 2:23pm | 452Read More...Shares of Zogenix, Inc. (NASDAQ: ZGNX) — a biopharma company,developing treatments for patients with rare central nervous system conditions with limited or no treatment options — could be in for further upside. This is on top of the triple-digit gains posted in late September...
-
Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments
Friday, August 25, 2017 - 12:03pm | 695Read More...Adamas Pharmaceuticals Inc (NASDAQ: ADMS) shares were on a tear Friday following that the FDA has approved its GOCOVRI extended release capsules for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without dopaminergic medications. At the time of...
-
Why Arena Is Taking Center Stage Today
Tuesday, July 11, 2017 - 11:53am | 609Read More...Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares are on a roll on Tuesday, rising by about one-half on over 10 times their average volume. The stock is now trading at its highest level in nearly two years. For those keen to the know the reason behind the jump, here are the details. Catalyst...
-
Arena Upgraded, Analyst Sees 44% Upside
Friday, July 7, 2017 - 9:09am | 344Read More...With phase 2 results expected to be released in the near future, JMP analyst Jason Butler upgraded his rating on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Market Outperform with a $27 price target. “We believe the stock’s current valuation under-appreciates the potential for...
-
Analyst Sees Nearly 100% Upside In Egalet Following Latest Clinical Data
Monday, December 19, 2016 - 10:52am | 247Read More...Egalet Corp (NASDAQ: EGLT) shares are up another 2 percent in early Monday trading following a big 12.5 percent jump on Friday after the company released a new round of trial data for a key drug candidate. According to JMP Securities, the Egalet rally is far from over. Egalet announced...
-
UPDATE: JMP Securities Initiates Coverage On Intra-Cellular Therapies
Tuesday, December 23, 2014 - 10:43am | 120Read More...Jason Butler of JMP Securities initiated coverage of Intra-Cellular Therapies (NASDAQ: ITCI) on Tuesday with a Market Outperform rating and $26 price target. “Intra-Cellular Therapies is focused on the development of ITI-007, a novel antipsychotic candidate currently in Phase 3 development for the...
-
JMP, Needham Doubtful Over Chelsea Therapeutics Receiving Additional Bids
Friday, May 9, 2014 - 1:54pm | 156Read More...JMP & Needham suggest that Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is not likely to see other offers following the Lundneck bid. JMP analyst Jason Butler called Chelsea Therapeutics sale process “thorough” and sees a competing bid as “unlikely.” Butler added that the company's...
-
JMP Securities Initiated Coverage on Chelsea Therapeutics and SolarWinds
Thursday, December 19, 2013 - 4:58pm | 278Read More...JMP Securities initiated coverage on Chelsea Therapeutics International (NASDAQ: CHTP) and SolarWinds (NYSE: SWI) with a Market Outperform rating in JMP's morning note published Thursday. Analyst Jason Butler initiated coverage on Chelsea Therapeutics with a Market Outperform rating and $8.00...
